- Highlights
- Full Text
[1:46] ..." Now this was a mid stage human clinical trial. Obviously I'm assuming that there was some positive results in the early test."...
[1:54] ..." Yes that's correct the compound first of all -- very substantial tax in animal models both anxiety and depression it -- very nice result in animal models attention deficit disorder that drug went into phase one safety studies and some say it's too early studies and anxiety. And we get paid three study in generalized anxiety disorder where patients who had significant anxiety came and also pat symptoms of depression so we have patients with diagnosed with anxiety disorder but as most patients with these kinds of diseases have significant what we call crossovers sitcoms for depression. In in that phase"...
[4:16] ..." along we will -- starting. -- to -- to be studies in alzheimer's disease within the next quarter these these two studies are in patients with alzheimer's disease as I've mentioned will be mild moderate alzheimer's disease "...
[0:00]" How long was the research continuing and let. The decision."
[0:05]" so some. PRX triple zero -- three it was the first drug that the company the private company -- pretext pharmaceuticals brought to the clinic up patents were granted in 2000. Six recently they've run out to 2024 this is the compound went into the clinic in 2004 and due to the negative results from our depression study a very good well run study it was a phase two -- study. So the second phase late stage development really designed to be and Kona coast study and we were unable to to show clinically significant all right statistically significant difference between -- drug and -- it is true that the placebo rate in that study was higher than we expected and so that patients with who came into the study who had moderate to severe depression. Actually to get better on placebo quite."
[1:03]" Actually actually but that's part of the difficult in the depression studies and of course were all pleased that the -- got better but -- the drug can't distinguish itself in this study of this nature especially a small company really have to stop development and be very. Be very disciplined about that. So we decided based on the data from this pays to be studied at the efficacy of the drug wasn't significant enough. To warrant for the development I should say that the safety in the tower -- the drug was excellent and if there were additional indications in the future -- Where this type of product might be useful. -- certainly a drug that could be administered to humans safely."
[1:46]" Now this was a mid stage human clinical trial. Obviously I'm assuming that there was some positive results in the early test."
[1:54]" Yes that's correct the compound first of all -- very substantial tax in animal models both anxiety and depression it -- very nice result in animal models attention deficit disorder that drug went into phase one safety studies and some say it's too early studies and anxiety. And we get paid three study in generalized anxiety disorder where patients who had significant anxiety came and also pat symptoms of depression so we have patients with diagnosed with anxiety disorder but as most patients with these kinds of diseases have significant what we call crossovers sitcoms for depression. In in that phase three study on the drug showed a very modest benefit on anxiety it didn't hit statistical significance but it showed very robust clinically and statistically significant reduction in. Symptoms of depression. Those those results had -- been in the depressed population as a result would have been sufficient for this study to be positive. But that study that was in the anxiety patients and so. We eat based on those data. In what was the late stage anxiety steady pace in the data we moved ahead in depression because the effect of the drug seemed to be much more -- on depression symptoms which tend to be about pessimistic -- unfortunately in some cases suicidal thoughts -- anxious thought in this sort."
[3:26]" Doctor what does this mean. Off financially for the company to make a decision like this."
[3:31]" Well you know and one sort of ironic that it saves the company money because we stop all development of -- kind and it doesn't cost anymore and so in terms of our budget this year well actually expanding slightly less money than we expected over although obviously we're in the business of making drugs. So this is one of our late stage products is a disappointment in the company but it doesn't actually back the 2008 budget."
[3:59]" I appreciate your your interest -- Moving forward what other drug development programs are under way and -- what are the prospects of for those drugs."
[4:06]" Yeah so one of the advantages we have here ethics is that that we actually have prior to this amount that we had five drugs in the clinic we don't have four I'm so we do a lot of things moving along we will -- starting. -- to -- to be studies in alzheimer's disease within the next quarter these these two studies are in patients with alzheimer's disease as I've mentioned will be mild moderate alzheimer's disease "
Del.icio.us
Digg
Reddit
